Compare Stocks

Date Range: 

 EpizymeAffimedHumanigenCollegium PharmaceuticalAmphastar Pharmaceuticals
SymbolNASDAQ:EPZMNASDAQ:AFMDNASDAQ:HGENNASDAQ:COLLNASDAQ:AMPH
Price Information
Current Price$6.81$9.70$18.40$21.94$18.05
52 Week RangeBuyBuyBuyHoldHold
MarketRank™
Overall Score1.91.61.71.61.5
Analysis Score3.33.53.42.12.1
Community Score2.82.93.82.52.6
Dividend Score0.00.00.00.00.0
Ownership Score2.50.80.80.00.8
Earnings & Valuation Score0.60.60.63.11.9
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldHold
Consensus Price Target$16.33$13.80$30.14$25.00$21.67
% Upside from Price Target139.84% upside42.27% upside63.82% upside13.95% upside20.04% upside
Trade Information
Market Cap$694.46 million$953.38 million$1.08 billion$772.38 million$860.80 million
Beta1.762.81-0.791.270.87
Average Volume1,125,3423,135,7602,319,113503,794187,986
Sales & Book Value
Annual Revenue$23.80 million$23.96 millionN/A$296.70 million$322.36 million
Price / Sales29.1839.79N/A2.602.67
CashflowN/AN/AN/AN/A$0.74 per share
Price / CashN/AN/AN/AN/A24.42
Book Value$3.22 per share$0.57 per share($0.63) per share$2.61 per share$9.11 per share
Price / Book2.1117.02N/A8.411.98
Profitability
Net Income$-170,290,000.00$-36,250,000.00$-10,290,000.00$-22,720,000.00$48.94 million
EPS($1.93)($0.56)N/A($0.68)$0.36
Trailing P/E RatioN/AN/A0.0044.78128.93
Forward P/E RatioN/AN/A4.4913.3016.26
P/E GrowthN/AN/AN/A0.73N/A
Net Margins-1,899.35%-172.01%N/A5.71%1.97%
Return on Equity (ROE)-83.45%-99.24%-302.90%12.64%5.50%
Return on Assets (ROA)-52.66%-37.40%-174.74%3.15%4.04%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.33%N/AN/A1.27%0.07%
Current Ratio8.95%2.24%6.19%1.08%2.86%
Quick Ratio8.71%2.24%6.19%1.01%1.73%
Ownership Information
Institutional Ownership Percentage89.82%52.33%30.18%N/A55.08%
Insider Ownership Percentage16.30%N/A37.50%8.08%29.80%
Miscellaneous
Employees304137102341,980
Shares Outstanding101.98 million98.29 million58.66 million35.20 million47.69 million
Next Earnings Date8/3/2021 (Estimated)6/22/2021 (Estimated)5/21/2021 (Estimated)8/4/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalyst Biosciences (CBIO), Zoetis (ZTS) and Bluebird Bio (BLUE)Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalyst Biosciences (CBIO), Zoetis (ZTS) and Bluebird Bio (BLUE)
smarteranalyst.com - May 6 at 9:32 PM
Amphastar: Q1 Earnings SnapshotAmphastar: Q1 Earnings Snapshot
sfgate.com - May 6 at 9:32 PM
Recap: Amphastar Pharmaceuticals Q1 EarningsRecap: Amphastar Pharmaceuticals Q1 Earnings
benzinga.com - May 6 at 9:32 PM
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top EstimatesAmphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
finance.yahoo.com - May 6 at 9:32 PM
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021
finance.yahoo.com - May 6 at 4:32 PM
Amphastar Pharmaceuticals (AMPH) Set to Announce Earnings on ThursdayAmphastar Pharmaceuticals (AMPH) Set to Announce Earnings on Thursday
americanbankingnews.com - May 5 at 6:58 AM
Sanofi Wins $17.2M Fees, Expenses After Ditching FCA SuitSanofi Wins $17.2M Fees, Expenses After Ditching FCA Suit
law360.com - May 4 at 10:02 PM
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Consensus Rating of "Hold" by BrokeragesAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Consensus Rating of "Hold" by Brokerages
americanbankingnews.com - May 4 at 12:20 PM
Amphastar Pharma Gets Approval For Its Morphine Sulfate Injection- Quick FactsAmphastar Pharma Gets Approval For Its Morphine Sulfate Injection- Quick Facts
nasdaq.com - May 3 at 10:54 AM
Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate InjectionAmphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection
finance.yahoo.com - May 3 at 10:54 AM
$97.12 Million in Sales Expected for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) This Quarter$97.12 Million in Sales Expected for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) This Quarter
americanbankingnews.com - April 30 at 3:00 AM
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May ...Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May ...
apnews.com - April 29 at 8:57 AM
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021
finance.yahoo.com - April 29 at 8:57 AM
$0.19 EPS Expected for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) This Quarter$0.19 EPS Expected for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) This Quarter
americanbankingnews.com - April 28 at 10:34 AM
Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Will Announce Quarterly Sales of $97.12 Million Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Will Announce Quarterly Sales of $97.12 Million
americanbankingnews.com - April 13 at 3:32 AM
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
finance.yahoo.com - April 9 at 9:20 AM
Have Insiders Been Selling Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares This Year?Have Insiders Been Selling Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares This Year?
nasdaq.com - April 7 at 9:20 AM
Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare ConferenceAmphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 6:32 PM
Raymond James Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)Raymond James Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)
smarteranalyst.com - April 5 at 7:07 PM
Amphastar Pharmaceuticals (AMPH) Receives a Buy from Northland SecuritiesAmphastar Pharmaceuticals (AMPH) Receives a Buy from Northland Securities
smarteranalyst.com - March 30 at 12:22 PM
FDA Approves New Drug Application For Amphastar’s Dextrose InjectionFDA Approves New Drug Application For Amphastar’s Dextrose Injection
finance.yahoo.com - March 30 at 12:22 PM
Amphastar Pharmaceuticals Receives FDA Approval for Dextrose InjectionAmphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
finance.yahoo.com - March 29 at 6:19 AM
Raymond James Keeps a Hold Rating on Amphastar Pharmaceuticals (AMPH)Raymond James Keeps a Hold Rating on Amphastar Pharmaceuticals (AMPH)
smarteranalyst.com - March 16 at 10:05 AM
Amphastar: Q4 Earnings SnapshotAmphastar: Q4 Earnings Snapshot
finance.yahoo.com - March 15 at 6:56 PM
Amphastar: Q4 Earnings Snapshot | Raleigh News & ObserverAmphastar: Q4 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - March 15 at 6:56 PM
DateCompanyBrokerageAction
5/7/2021EpizymeMorgan StanleyLower Price Target
5/7/2021EpizymeSVB LeerinkUpgrade
3/30/2021EpizymeCredit Suisse GroupInitiated Coverage
2/24/2021EpizymeCitigroupLower Price Target
2/23/2021EpizymeWedbushReiterated Rating
12/21/2020EpizymeJefferies Financial GroupDowngrade
11/9/2020EpizymeBarclaysLower Price Target
5/5/2020EpizymeOppenheimerReiterated Rating
2/25/2020EpizymeHC WainwrightReiterated Rating
1/24/2020EpizymeCowenBoost Price Target
4/12/2021AffimedBMO Capital MarketsBoost Price Target
3/30/2021AffimedWells Fargo & CompanyBoost Price Target
8/9/2020AffimedLaidlawReiterated Rating
10/11/2018AffimedSunTrust BanksLower Price Target
5/5/2021HumanigenRoth CapitalBoost Price Target
2/23/2021HumanigenJPMorgan Chase & Co.Initiated Coverage
12/23/2020HumanigenNational SecuritiesInitiated Coverage
10/21/2020HumanigenCantor FitzgeraldReiterated Rating
12/29/2020Collegium PharmaceuticalNeedham & Company LLCReiterated Rating
7/14/2020Collegium PharmaceuticalBWS FinancialInitiated Coverage
5/26/2020Collegium PharmaceuticalGuggenheimInitiated Coverage
2/28/2020Collegium PharmaceuticalWilliam BlairReiterated Rating
2/12/2020Collegium PharmaceuticalPiper SandlerBoost Price Target
10/5/2020Amphastar PharmaceuticalsNorthland SecuritiesUpgrade
3/13/2019Amphastar PharmaceuticalsPiper Jaffray CompaniesDowngrade
(Data available from 5/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.